Kallyope

Kallyope is a startup focused on developing new drugs based on the gut-brain axis mechanism. The platform integrates cutting-edge technologies, including single-cell sequencing, genetics, signaling pathway imaging, neuroimaging, and bioinformatics. Leveraging its innovative technology, Kallyope has initiated several drug discovery programs, initially concentrating on metabolic and neurological diseases, with plans to expand to all disease areas involving the gut and gut-brain axis. Over the past four years, Kallyope has built a portfolio of programs targeting novel disease objectives. To support these programs, the company has established industry-leading capabilities in designing orally administered small-molecule drugs that selectively target the gut without affecting other parts of the body.Additionally, the company announced that its weight-loss product stimulating satiety will enter clinical trials later this year. Meanwhile, a second program targeting intestinal barrier function, which may be relevant to inflammatory bowel disease (IBD) and several other conditions, is expected to move into clinical testing soon.